An appellate court panel ruled Tuesday that drug manufacturers may not impose 340B rebates without approval from the U.S. Department of Health and Human Services (HHS). | The ruling upheld a previous decision that pharma companies cannot impose rebates without HHS Secretary approval.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Another legislative vehicle fine-tuning the contentious 340B drug discount program has been introduced by a bipartisan group of…
The Health Resources & Services Administration has unveiled its formal plans for a revised version of its contentious 340B Rebate…
After years of investigation, the outgoing chairman of the Senate Health, Education, Labor and Pensions Committee has released…
HRSA unveils revised 340B rebate pilot letting drugmakers deny rebates for some drugs.
Eli Lilly and Company said Monday evening that it will soon end 340B discount pricing for some of the hospitals that have not met…
The Health Resources and Services Administration is again pushing to include rebates in the drug discount program after a failed…
